Clinical Trials

Multiple Myeloma, Recurrence

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

261 enrolled

Phase 2/3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02343042 2026-05-04

STOMP

Phase 1/2 Active not recruiting

300 enrolled

Multiple Myeloma, Recurrence

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04756726 2026-03-25

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

224 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT01615029 2026-03-16

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

45 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1/2 Terminated

200 enrolled

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

160 enrolled

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

54 enrolled 17 charts

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT02939183 2024-09-26

INTREPID-1

61 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

114 enrolled

Multiple Myeloma, Recurrence

NCT03110562 2024-08-21

BOSTON

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT02654990 2024-07-12

PANORAMA_3

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT06232707 2024-05-31

ALUMMINATE

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT05647512 2023-11-18

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02807454 2023-02-21

FUSIONMM-003

37 enrolled 21 charts

Multiple Myeloma, Recurrence

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled

Multiple Myeloma, Recurrence

NCT03029234 2022-05-25

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

126 enrolled 30 charts

Multiple Myeloma, Recurrence

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Multiple Myeloma, Recurrence

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Phase 1 Unknown

60 enrolled

Multiple Myeloma, Recurrence

NCT01712789 2022-01-10

STRATUS

682 enrolled 23 charts

Multiple Myeloma, Recurrence

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

8 enrolled 12 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT00773838 2021-04-01

MK-0683-095

143 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT03512353 2021-01-08

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

7 enrolled 32 charts

Multiple Myeloma, Recurrence

NCT00708292 2020-12-17

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

29 enrolled

Multiple Myeloma, Recurrence

NCT00642954 2020-11-18

MK-0683-074

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

16 enrolled

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02348528 2019-11-12

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

65 enrolled

Multiple Myeloma, Recurrence

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3 Terminated

147 enrolled